Unveiling targeted cell-free DNA methylation regions through paired methylome analysis of tumor and normal tissues

Liquid biopsy analysis of cell-free DNA (cfDNA) has revolutionized cancer research by enabling non-invasive assessment of tumor-derived genetic and epigenetic changes. In this study, we conducted a comprehensive paired-sample differential methylation analysis (psDMR) on reprocessed methylation data from two large datasets, CPTAC and TCGA, to identify and validate differentially methylated regions (DMRs) as potential cfDNA biomarkers for head and neck squamous cell carcinoma (HNSC). Our hypothesis is that the paired sample test provides a more suitable and powerful approach for the analysis of heterogeneous cancers like HNSC. The psDMR analysis revealed a significant number of overlapped hypermethylated DMRs between two datasets, indicating the reliability and relevance of these regions for cfDNA methylation biomarker discovery. We identified several candidate genes, including CALCA, ALX4, and HOXD9, which have been previously established as liquid biopsy methylation biomarkers in various cancer types. Furthermore, we demonstrated the efficacy of targeted region analysis using cfDNA methylation data from oral cavity squamous cell carcinoma and nasopharyngeal carcinoma patients, further validating the utility of psDMR analysis in prioritizing cfDNA methylation biomarkers. Overall, our study contributes to the development of cfDNA-based approaches for early cancer detection and monitoring, expanding our understanding of the epigenetic landscape of HNSC, and providing valuable insights for liquid biopsy biomarker discovery not only in HNSC and other cancer types.

[1]  H. Noushmehr,et al.  Noninvasive approaches to detect methylation-based markers to monitor gliomas , 2022, Neuro-oncology advances.

[2]  T. Padhya,et al.  Plasma cell‐free DNA methylome profiling in pre‐ and post‐surgery oral cavity squamous cell carcinoma , 2022, medRxiv.

[3]  He Duan,et al.  Correlation between RASSF1A Methylation in Cell-Free DNA and the Prognosis of Cancer Patients: A Systematic Review and Meta-Analysis , 2022, Journal of oncology.

[4]  Xiaoxi Zhou,et al.  Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta‐analysis update , 2021, Thoracic cancer.

[5]  C. E. van der Schoot,et al.  Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid Tumors , 2021, JCO Precision Oncology.

[6]  Jie Ma,et al.  A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer , 2021, Scientific Reports.

[7]  W. Liang,et al.  Accurate diagnosis of pulmonary nodules using a non-invasive DNA methylation test. , 2021, The Journal of clinical investigation.

[8]  C. Ding,et al.  Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy , 2021, Proceedings of the National Academy of Sciences.

[9]  Alexander R. Pico,et al.  Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. , 2021, Cancer cell.

[10]  A. Paço,et al.  Methylation in HOX Clusters and Its Applications in Cancer Therapy , 2020, Cells.

[11]  M. Fassan,et al.  Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients , 2020, International journal of molecular sciences.

[12]  J. McPherson,et al.  Sensitive tumour detection and classification using plasma cell-free DNA methylomes , 2018, Nature.

[13]  P. Laird,et al.  SeSAMe: reducing artifactual detection of DNA methylation by Infinium BeadChips in genomic deletions , 2018, Nucleic acids research.

[14]  Susan E. Groening,et al.  Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study , 2018, British Journal of Cancer.

[15]  Wenbin Liu,et al.  ALX4, an epigenetically down regulated tumor suppressor, inhibits breast cancer progression by interfering Wnt/β-catenin pathway , 2017, Journal of experimental & clinical cancer research : CR.

[16]  Yoko Yamamoto,et al.  LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer , 2017, Oncotarget.

[17]  R. Grenman,et al.  Prognostic significance of the methylation of Wnt pathway antagonists—CXXC4, DACT2, and the inhibitors of sonic hedgehog signaling—ZIC1, ZIC4, and HHIP in head and neck squamous cell carcinomas , 2016, Clinical Oral Investigations.

[18]  D. O. Vidal,et al.  MGMT and CALCA promoter methylation are associated with poor prognosis in testicular germ cell tumor patients , 2016, Oncotarget.

[19]  Guangyou Duan,et al.  A prospective observational cohort study , 2016 .

[20]  Daria A. Gaykalova,et al.  Outlier Analysis Defines Zinc Finger Gene Family DNA Methylation in Tumors and Saliva of Head and Neck Cancer Patients , 2015, PloS one.

[21]  D. Dietrich,et al.  SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  J. Califano,et al.  A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma , 2011, International journal of cancer.

[23]  H S Sacks,et al.  Meta-analysis: an update. , 1996, The Mount Sinai journal of medicine, New York.

[24]  A. Sood,et al.  Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. , 2011, Gynecologic oncology.

[25]  P. Ladenson,et al.  Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.